Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ACET

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ACET

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Adicet Bio Inc

ACET
Current price
0.76 USD +0.0024 USD (+0.32%)
Last closed 0.78 USD
ISIN US0070021086
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 61 188 560 USD
Yield for 12 month -40.44 %
1Y
3Y
5Y
10Y
15Y
ACET
21.11.2021 - 28.11.2021

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts. Address: 131 Dartmouth Street, Boston, MA, United States, 02116

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

6.00 USD

P/E Ratio

Dividend Yield

Financials ACET

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ACET

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

-6 098 000 USD

Current Quarter

Last Quarter

EBITDA -120 132 000 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -32.68 %
PEG Ratio 0.82
Return On Equity TTM -55.83 %
Wall Street Target Price 6.00 USD
Revenue TTM
Book Value 1.95 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100.00 %
Dividend Yield
Gross Profit TTM 24 990 000 USD
Earnings per share -1.29 USD
Diluted Eps TTM -1.29 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation ACET

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.14
Price Sales TTM 9.72
Enterprise Value EBITDA -1.21
Price Book MRQ 0.37

Technical Indicators ACET

For 52 Weeks

0.45 USD 1.70 USD
50 Day MA 0.68 USD
Shares Short Prior Month 2 891 936
200 Day MA 0.92 USD
Short Ratio 5.64
Shares Short 3 316 444
Short Percent 4.68 %